Zibotentan (INN; development code ZD4054) is an experimental anti-cancer drug candidate in development by AstraZeneca.[1] It is an endothelin receptor antagonist.[2]
Names | |
---|---|
Preferred IUPAC name
N-(3-Methoxy-5-methylpyrazin-2-yl)-2-[4-(1,3,4-oxadiazol-2-yl)phenyl]pyridine-3-sulfonamide | |
Other names
ZD4054
| |
Identifiers | |
| |
3D model (JSmol)
|
|
ChemSpider |
|
ECHA InfoCard | 100.171.075 |
| |
PubChem CID
|
|
UNII |
|
| |
| |
Properties | |
C19H16N6O4S | |
Molar mass | 424.44 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
verify (what is ?)
Infobox references
|
Zibotentan was granted fast track status for the treatment of prostate cancer by the FDA.
It failed a phase III clinical trial for prostate cancer,[3] but other trials are planned.[4] Tolerability of zibotentan plus docetaxel has been evaluated.[5]
Zibotentan has also been studied in clinical trials for treatment of breast cancer, colorectal cancer, non-small cell lung cancer, ovarian cancer, scleroderma-related renal disease,[6] bone metastasis, and heart failure.[7]